Horizon Pharma (HZNP) Flagging After Hours

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Horizon Pharma ( HZNP) as a post-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Horizon Pharma as such a stock due to the following factors:

  • HZNP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $88.4 million
  • HZNP is down 2.4% today from today's close

EXCLUSIVE OFFER: Get the inside scoop on opportunities in HZNP with the Ticky from Trade-Ideas. See the FREE profile for HZNP NOW at Trade-Ideas

More details on HZNP:

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. Currently there are nine analysts that rate Horizon Pharma a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Horizon Pharma has been 4 million shares per day over the past 30 days. Horizon has a market cap of $5.11 billion and is part of the health care sector and drugs industry. The stock has a beta of 2.26 and a short float of 10.9% with 4.37 days to cover. Shares are up 159.3% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Dow Scores Ninth Straight Record Close With Tiny Gains, S&P 500 at All-Time High

Dow Is Back on Track to Close at a Record High as Consumer Staples Lead

Energy Losses Put Dow's Record-Breaking Streak in Jeopardy

Biotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher